Background:
Venous thromboembolism (VTE) prophylaxis remains underutilized, particularly in cancer patients. We explored clinical predictors of prophylaxis in hospitalized cancer patients before the onset of acute VTE.
Methods:
In the SWiss Venous ThromboEmbolism Registry, 257 cancer patients (61 +/- 15 years) with acute VTE and prior hospitalization for acute medical illness or surgery within 30 days (91% were at high risk with Geneva VTE risk score > or =3) were enrolled.
Results:
Overall, 153 (60%) patients received prophylaxis (49% pharmacological and 21% mechanical) before the onset of acute VTE. Outpatient status at the time of VTE diagnosis [odds ratio (OR) 0.31, 95% confidence interval (CI) 0.18-0.53], ongoing chemotherapy (OR 0.51, 95% CI 0.31-0.85), and recent chemotherapy (OR 0.53, 95% CI 0.32-0.88) were univariately associated with the absence of VTE prophylaxis. In multivariate analysis, intensive care unit admission within 30 days (OR 7.02, 95% CI 2.38-20.64), prior deep vein thrombosis (OR 3.48, 95% CI 2.14-5.64), surgery within 30 days (OR 2.43, 95% CI 1.19-4.99), bed rest >3 days (OR 2.02, 95% CI 1.08-3.78), and outpatient status (OR 0.38, 95% CI 0.19-0.76) remained the only independent predictors of thromboprophylaxis.
Conclusions:
Although most hospitalized cancer patients were at high risk, 40% did not receive any prophylaxis before the onset of acute VTE. There is a need to improve thromboprophylaxis in cancer patients, particularly in the presence of recent or ongoing chemotherapy.
Citing Articles
A Three-year Retrospective Study Looking at Preventing Hospital Acquired Thrombosis.
Kammath V, Gupta A, Bald A, Hope G, Kansal N, Al Samaraee A
Cardiovasc Hematol Agents Med Chem. 2024; 22(2):212-222.
PMID: 38288832
DOI: 10.2174/0118715257269027231228114930.
A Rare Presentation of Acute Kidney Injury in Diffuse Large B-Cell Lymphoma: A Case Report.
Saleh M, Salih N, Kakakhel M, Ullah I, Siraj H, Tariq M
Cureus. 2023; 15(9):e45642.
PMID: 37868496
PMC: 10589075.
DOI: 10.7759/cureus.45642.
Rationale, design and methodology of TESEO study: a registry of thrombosis and neoplasia of SEOM (Spanish Society of Medical Oncology).
Munoz-Langa J, Jimenez-Fonseca P, Carmona-Bayonas A, de Castro E, Perez-Segura P, Canovas M
Clin Transl Oncol. 2020; 23(4):799-811.
PMID: 32789772
DOI: 10.1007/s12094-020-02472-x.
Assessment of adherence to cancer-associated venous thromboembolism guideline and pharmacist's impact on anticoagulant therapy.
Kandemir E, Bayraktar-Ekincioglu A, Kilickap S
Support Care Cancer. 2020; 29(3):1699-1709.
PMID: 32776163
DOI: 10.1007/s00520-020-05669-6.
Improvement of appropriate pharmacological prophylaxis in hospitalised cancer patients with a multiscreen e-alert system: a single-centre experience.
Figueroa R, Alfonso A, Lopez-Picazo J, Gil-Bazo I, Garcia-Mouriz A, Hermida J
Clin Transl Oncol. 2018; 21(6):805-809.
PMID: 30446983
DOI: 10.1007/s12094-018-1986-1.
Insights into venous thromboembolism prevention in hospitalized cancer patients: Lessons from a prospective study.
Figueroa R, Alfonso A, Lopez-Picazo J, Gil-Bazo I, Garcia-Mouriz A, Hermida J
PLoS One. 2018; 13(8):e0200220.
PMID: 30071038
PMC: 6071981.
DOI: 10.1371/journal.pone.0200220.
Assessment of the Risk of Venous Thromboembolism in Medical Inpatients using the Padua Prediction Score and Caprini Risk Assessment Model.
Zhou H, Hu Y, Li X, Wang L, Wang M, Xiao J
J Atheroscler Thromb. 2018; 25(11):1091-1104.
PMID: 29540637
PMC: 6224205.
DOI: 10.5551/jat.43653.
Venous thromboembolism in hospitalized patients receiving chemotherapy for malignancies at Japanese community hospital: prospective observational study.
Kitayama H, Kondo T, Sugiyama J, Kurimoto K, Nishino Y, Hirayama M
BMC Cancer. 2017; 17(1):351.
PMID: 28525975
PMC: 5438527.
DOI: 10.1186/s12885-017-3326-1.
Venous thromboembolism in cancer patients: an underestimated major health problem.
Khalil J, Bensaid B, Elkacemi H, Afif M, Bensaid Y, Kebdani T
World J Surg Oncol. 2015; 13:204.
PMID: 26092573
PMC: 4486121.
DOI: 10.1186/s12957-015-0592-8.
Implementing thrombosis guidelines in cancer patients: a review.
Farge-Bancel D, Bounameaux H, Brenner B, Buller H, Kakkar A, Pabinger I
Rambam Maimonides Med J. 2014; 5(4):e0041.
PMID: 25386357
PMC: 4222430.
DOI: 10.5041/RMMJ.10175.
Improved compliance with venous thromboembolism pharmacologic prophylaxis for patients with gynecologic malignancies hospitalized for nonsurgical indications did not reduce venous thromboembolism incidence.
Prescott L, Kidin L, Downs R, Cleveland D, Wilson G, Munsell M
Int J Gynecol Cancer. 2014; 25(1):152-9.
PMID: 25365592
PMC: 4272626.
DOI: 10.1097/IGC.0000000000000312.
Thrombosis as a complication of central venous access in pediatric patients with malignancies: a 5-year single-center experience.
Wiegering V, Schmid S, Andres O, Wirth C, Wiegering A, Meyer T
BMC Hematol. 2014; 14(1):18.
PMID: 25317335
PMC: 4195887.
DOI: 10.1186/2052-1839-14-18.
Cancer-related coagulopathy (Trousseau's syndrome): review of the literature and experience of a single center of internal medicine.
Dammacco F, Vacca A, Procaccio P, Ria R, Marech I, Racanelli V
Clin Exp Med. 2013; 13(2):85-97.
PMID: 23456539
DOI: 10.1007/s10238-013-0230-0.
Thromboprophylaxis guidelines in cancer with a primary focus on ambulatory patients receiving chemotherapy: a review from the Southern Network on Adverse Reactions (SONAR).
Maxwell W, Bennett C
Semin Thromb Hemost. 2012; 38(8):759-67.
PMID: 23111863
PMC: 4017864.
DOI: 10.1055/s-0032-1328893.